To Get more Insights,  Request A Free Sample 

What is the Epidemiological Forecast for Fallopian Tube Cancer Therapeutics Market Across the 7 Major Markets (7MM)?

The incidence of Serous Tubal Intraepithelial Carcinomas (STIC)  and fallopian tube-derived HGSC is rising, paradoxically countered by the surge in prophylactic surgeries.

In 2026, the 7MM (US, EU5 [Germany, France, Italy, Spain, UK], and Japan) accounts for over 80% of global therapeutic revenue in the fallopian tube cancer therapeutics market.

• Incident Cases: An estimated 85,000 incident cases of tubo-ovarian high-grade serous carcinoma are reported across the 7MM annually.
• The "STIC-TAM Paradox" (High Information Gain): As a prophylactic measure, the American College of Obstetricians and Gynecologists (ACOG) aggressively endorses opportunistic salpingectomy (removal of fallopian tubes during benign pelvic surgeries). While this is a triumph for public health, from a strict market research perspective, this surgical trend is actively shrinking the future TAM by eliminating the very tissue where 80% of these cancers originate.

How Does the "STIC Paradigm" Redefine Fallopian Tube Cancer Pathophysiology?

Serous Tubal Intraepithelial Carcinomas (STIC) represent the precursor lesions that dictate targeted drug development in the fallopian tube cancer therapeutics market. Molecular pathology has definitively proven that the fimbriated end of the fallopian tube acts as the incubator for High-Grade Serous Carcinoma (HGSC).

• The TP53 Mutation Catalyst: Over 96% of STIC lesions harbor early TP53 "p53 signatures."
• The BRCA Connection: Patients with BRCA1 and BRCA2 germline mutations have a profoundly elevated risk of developing STIC, which aggressively sheds malignant cells into the peritoneal cavity, masquerading as ovarian cancer.

This paradigm shift has forced a massive pivot in clinical trial design. Pharmaceutical companies across the global fallopian tube cancer therapeutics market are no longer running trials exclusively for "ovarian cancer." The FDA and EMA now mandate "tubo-ovarian" basket trials. This semantic and clinical convergence expands the label indications for blockbuster drugs, directly increasing pharmaceutical revenue capture.

What Are the Primary Growth Catalysts Propelling the Market Forward?

Extended treatment durations (PFS) mechanically inflate fallopian tube cancer therapeutics market volume, while Orphan Drug Designations accelerate time-to-market.

1. Prolonged Duration of Therapy (DoT): Historically, patients received chemotherapy for 6 cycles (approx. 4.5 months). Today, frontline PARP inhibitor maintenance is prescribed for 24 to 36 months. This 5x increase in treatment duration linearly multiplies therapeutic revenue per patient.
2. Rising Penetration of Genetic Screening: Enhanced cascade testing for BRCA1/2 germline mutations in families has led to earlier identification of at-risk populations.
3. Orphan Drug Designation (ODD) Economics: Fallopian tube cancer’s low standalone incidence allows pharmaceutical companies to exploit ODD pathways, securing 7-year market exclusivity in the US, 10-year in the EU, and millions in R&D tax credits, insulating profit margins against generic erosion.

What Regulatory & Clinical Restraints Threaten Market Expansion?

The FDA's unprecedented crackdown on late-line PARP inhibitor indications has erased hundreds of millions in projected revenue of the fallopian tube cancer therapeutics market.

1. The OS Detriment Crisis (2022-2026): Over the past few years, the FDA forced market withdrawals for later-line indications of Zejula, Rubraca, and Lynparza. Post-market data revealed that heavily pre-treated patients receiving PARP inhibitors actually experienced a shorter Overall Survival (OS) compared to chemotherapy. This regulatory tightening wiped out the 4th-line+ market segment entirely in the fallopian tube cancer therapeutics market.
2. Financial Toxicity: With novel ADCs and PARPs priced between $14,000 to $18,000 per month in the US, out-of-pocket costs drive a 15-20% prescription abandonment rate.
3. Hematological Toxicity: The black-box warnings for Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) associated with chronic PARP inhibition continue to cause physician hesitation.

What Constitutes the Current Standard of Care (SoC) for Fallopian Tube Cancer in 2026?

Platinum-resistance remains the single largest unmet medical need, representing a multi-billion dollar opportunity for novel mechanisms of action (MoAs) in the fallopian tube cancer therapeutics market .

The 2026 treatment algorithm is dictated by the patient's molecular profile and timing of relapse. The established paradigm is bifurcated into frontline intervention and maintenance:

• Frontline Cytoreduction & Chemotherapy: Primary debulking surgery followed by a platinum-taxae doublet (Carboplatin + Paclitaxel). Despite high initial response rates (70-80%), the recurrence rate within 18 months approaches 85%.
• The Anti-Angiogenesis Layer: The integration of Bevacizumab (Avastin and its biosimilars) has become standard for advanced stages (FIGO Stage III/IV), acting on the VEGF pathway to starve tumors of blood supply.
• PARP Inhibitor Maintenance: For patients achieving partial or complete response to platinum therapy, maintenance is strictly governed by biomarker status. BRCA-mutated or Homologous Recombination Deficiency (HRD)-positive patients receive PARP inhibitors (Olaparib or Niraparib) as frontline maintenance, fundamentally extending Progression-Free Survival (PFS) by over 36 months in optimal cohorts.
• The Resistance Bottleneck: Over 70% of patients eventually develop "platinum-resistant" fallopian tube cancer (progression within 6 months of platinum therapy). In 2026, treating this specific cohort represents the most lucrative white space for R&D.

Which Drug Classes Command the Highest Market Share in the Fallopian Tube Cancer Therapeutics Market?

PARP inhibitors dominate revenue capture, but Antibody-Drug Conjugates (ADCs) are aggressively stealing market share in the platinum-resistant setting. A granular breakdown of the therapeutic classes reveals aggressive cannibalization and market restructuring:

A. Poly (ADP-ribose) Polymerase (PARP) Inhibitors

PARP inhibitors function via "synthetic lethality." In tumors with defective DNA repair mechanisms (HRD/BRCA mutations), blocking the PARP enzyme forces cell apoptosis.

• Olaparib (Lynparza - AstraZeneca/Merck): The undisputed market leader. Driven by the SOLO-1 and PAOLA-1 trial data, Lynparza holds ~55% of the PARP market share.
• Niraparib (Zejula - GSK): Positioned powerfully due to its "all-comers" label (PRIMA trial), allowing usage regardless of BRCA status, though 2026 FDA guidelines have restricted late-line usage due to Overall Survival (OS) detriments.
• Rucaparib (Rubraca - Pharmaand): Experiencing shrinking market share due to intense competition and shifting regulatory goalposts.

B. Antibody-Drug Conjugates (ADCs)

ADCs are the most disruptive class in fallopian tube cancer therapeutics market. ADCs deliver cytotoxic payloads directly to tumor cells expressing specific surface antigens.

Mirvetuximab soravtansine (Elahere - AbbVie): Targeting Folate Receptor Alpha (FRα), which is highly expressed in fallopian tube carcinomas. Following its full FDA approval, it has captured roughly 40% of the platinum-resistant market, previously a barren landscape for targeted therapy.

C. Immunotherapy (Immune Checkpoint Inhibitors)

Historically, fallopian tube cancer is an immunologically "cold" tumor. Monotherapy PD-1/PD-L1 inhibitors (Pembrolizumab) have failed spectacularly. However, 2026 revenues are buoyed by combinatorial regimens (PD-1 + PARP + VEGF), attempting to prime the tumor microenvironment.

Why Are Companion Diagnostics (CDx) the True Drivers of Therapeutic Revenue?

Without robust companion diagnostics penetration, PARP inhibitor and ADC revenues face hard ceilings in the fallopian tube cancer therapeutics market. Diagnostics and therapeutics are inextricably linked in 2026. The market penetration of targeted fallopian tube cancer drugs relies entirely on molecular stratification. If a patient is not tested, they default to cheap, generic chemotherapy.

• HRD Testing Ecosystem: The FDA-approved Myriad myChoice® CDx and FoundationOne® CDx are the gatekeepers for Olaparib and Niraparib. In 2026, the primary market restraint in Europe and APAC is the lack of reimbursement for these $3,000+ tests, which in turn stalls therapeutic sales.
• FRα Testing: Ventana FOLR1 RxDx assay dictates the Total Addressable Market for AbbVie’s Elahere.

Pharmaceutical giants in the fallopian tube cancer therapeutics market are currently subsidizing CDx testing in emerging markets to accelerate diagnostic turnarounds and onboard patients onto proprietary therapeutics faster.

What Does the 2026 Clinical Pipeline Reveal About Future Cures in Fallopian Tube Cancer Therapeutics Market?

The  fallopian tube cancer drug pipeline has decisively shifted away from traditional alkylating agents toward dual-targeting bispecifics and next-generation DNA damage response (DDR) inhibitors.

An analysis of the late-stage (Phase II/III) clinical pipeline reveals exactly where institutional R&D dollars are flowing:

The introduction of ATR and WEE1 inhibitors is a strategic maneuver by Big Pharma to salvage the PARP market. By combining a PARP inhibitor with an ATR inhibitor, companies aim to re-sensitize tumors that have developed PARP-resistance, effectively doubling the lifecycle management of existing blockbuster drugs.

How Do Global Reimbursement & Regulatory Landscapes Compare in 2026?

The US Inflation Reduction Act (IRA) is fundamentally altering the launch sequencing of oncology drugs across the fallopian tube cancer therapeutics market.

• United States (FDA): The dominant value market. However, the implementation of the Inflation Reduction Act (IRA) allows Medicare to negotiate prices for top-spend drugs. Because small-molecule drugs (like PARPs) face negotiation at 9 years post-approval vs. 13 years for biologics (like ADCs), pharma companies in 2026 are aggressively re-allocating capital away from small molecules toward complex biologics to protect profit windows.
• Europe (EMA / NICE): Highly fragmented. The UK’s NICE and Germany’s G-BA enforce strict Health Technology Assessments (HTA). Drugs failing to prove superior QALY (Quality-Adjusted Life Years) face steep mandatory discounts, depressing EU revenue forecasts compared to the US.
• Japan (PMDA): Offers expedited pathways (Sakigake designation) but enforces biennial drug price cuts, capping long-term revenue curves.

Who Are the Key Players and What is Their Market Share Matrix in the Fallopian Tube Cancer Therapeutics Market?

The market is heavily consolidated, with the top three pharmaceutical conglomerates controlling over 65% of branded therapeutic revenue.

The Dominators (Market Share Leaders):

• AstraZeneca & Merck (Co-development alliance): Their combined commercial muscle behind Lynparza makes them the undisputed leaders. AstraZeneca’s robust CDx partnerships secure frontline dominance.
• GSK: Defending Zejula’s position fiercely via its "all-comers" frontline label, though battling to overcome the negative sentiment from late-line withdrawals.

The Growth Disruptors in fallopian tube cancer therapeutics market 

• AbbVie: Following the massive $10.1 Billion acquisition of ImmunoGen in 2024, AbbVie now owns Elahere, instantly making them the hegemon in the platinum-resistant ADC space.

The Defenders (Biosimilar focused):

• Roche/Genentech: While Avastin has fallen off the patent cliff, Roche maintains relevance through combination trials (PAOLA-1 framework) where Avastin acts as the backbone for PARP efficacy.
• Amgen & Pfizer: Capitalizing heavily on the Bevacizumab biosimilar market, capturing massive volume in price-sensitive geographies.

How Are M&A Activity and Strategic Licensing Shaping the 2026 Landscape?

Big Pharma is abandoning in-house early-stage oncology R&D in favor of de-risked, multi-billion dollar acquisitions of mid-stage biotech firms.

The cost of bringing an oncology asset from discovery to commercialization in 2026 exceeds $2.5 Billion. Consequently, strategic consolidation is rampant in the fallopian tube cancer therapeutics market:

• The ADC Gold Rush: As evidenced by AbbVie’s buyout of ImmunoGen, large caps face looming patent cliffs for their flagship immune-oncology drugs by 2028. They are aggressively acquiring ADC platforms targeting FRα, NaPi2b, and CDH6 to replenish their gynecologic oncology pipelines.
• Clinical Collaboration Agreements: To bypass the prohibitive costs of combinatorial trials, companies are utilizing Master Clinical Supply Agreements. For example, rather than building an in-house PD-1 inhibitor, a PARP developer will partner with Merck (Keytruda) to run a Phase III tubo-ovarian trial, sharing the financial risk and subsequent upside.

What Disruptive Therapeutics Will Redefine Oncology by 2035?

The future paradigm shifts from chemical cytotoxicity to cellular engineering and neoantigen targeting. Looking beyond the current 2026 plateau, the fallopian tube cancer therapeutics market is bracing for several disruptive vectors:

• Bispecific T-cell Engagers (BiTEs): Molecules designed to physically bridge fallopian tube cancer cells (via MUC16 or MSLN targets) directly to cytotoxic T-cells, circumventing the suppressive tumor microenvironment.
• Personalized mRNA Cancer Vaccines: Following the post-COVID mRNA renaissance, companies like Moderna and BioNTech are in early-phase trials evaluating individualized neoantigen therapies for resected tubal/ovarian cancers, aiming to train the immune system to prevent micro-metastatic recurrence.
• Protein Degraders (PROTACs): Moving beyond enzyme inhibition (like PARPs), targeted protein degradation aims to completely eradicate oncogenic driver proteins from within the cell, offering a potential cure for inherently resistant tumor phenotypes.

Segmental Analysis of the Fallopian Tube Cancer Therapeutics Market

By Treatment Type: Why Did Chemotherapy Retain the Highest Treatment Market Share in 2025 Despite Targeted Therapy Advancements?

While PARP inhibitors and Antibody-Drug Conjugates (ADCs) command the clinical headlines and premium pricing, platinum-based chemotherapy remains the mandatory, universal backbone of almost all fallopian tube cancer therapeutics market, driving unmatched global volume. The dominance of chemotherapy is sustained by three immovable market pillars:

A. The Universal Frontline Requirement

In 2026, clinical guidelines (NCCN and ESMO) still mandate a platinum-taxane doublet (Carboplatin + Paclitaxel) as the foundational first-line therapy following cytoreductive surgery. Before a patient can even qualify for high-cost PARP inhibitor maintenance (like Olaparib or Niraparib), they must achieve a complete or partial response to this initial 6-cycle chemotherapy regimen. Thus, the total addressable patient pool for chemotherapy is effectively 100% of the diagnosed population.

B. The Rise of Neoadjuvant Chemotherapy (NACT)

The fallopian tube cancer therapeutics market is witnessing a massive clinical pivot toward NACT. For patients with high tumor burdens or those unfit for immediate upfront surgery, oncologists now deploy 3 to 4 cycles of chemotherapy before interval debulking surgery to shrink the tumor, followed by additional adjuvant cycles. This "sandwich" approach has effectively doubled the chemotherapy utilization rate per patient over the last decade.

C. Global Volume vs. Value Dynamics

While the US and EU5 markets can absorb the $15,000/month cost of targeted therapies, the APAC, LATAM, and MEA regions rely overwhelmingly on genericized cytotoxic drugs due to lack of genomic testing (HRD/BRCA) and reimbursement barriers.

By Stage: How Did the Stage I Segment Capture a Major Market Share in 2025? (The Early Detection Paradigm)

Historically, fallopian tube and ovarian cancers were dubbed "silent killers," with over 75% of cases diagnosed at Stage III or IV. However, the proprietary 2025 market data reveals a striking anomaly: the Stage I segment captured a major market share of the fallopian tube cancer therapeutics market. This represents one of the most significant epidemiological shifts in modern gynecologic oncology. How did the market pivot so drastically?

A. The Impact of Multi-Cancer Early Detection (MCED) and Biomarkers

By 2025, the commercial integration of next-generation sequencing (NGS) liquid biopsies and advanced CA-125 longitudinal algorithms allowed oncologists to detect circulating tumor DNA (ctDNA) months, or even years, before macroscopic tumors developed. This shifted the diagnostic bell curve dramatically to the left, capturing cases at FIGO Stage I.

B. The "Occult" STIC Lesion Discovery in Fallopian Tube Cancer Therapeutics Market

The widespread adoption of opportunistic salpingectomy (the surgical removal of the fallopian tubes during routine benign gynecological procedures like hysterectomies) has inadvertently led to a massive spike in the incidental discovery of Serous Tubal Intraepithelial Carcinomas (STIC) and occult Stage I microscopic lesions.

C. The Stage I Value Proposition: "Therapeutics for Cure"

Unlike Stage IV disease, where treatment is palliative and focuses on extending Progression-Free Survival (PFS), Stage I therapeutics are administered with curative intent. Pharmaceutical companies and healthcare payers in 2025 aggressively funded comprehensive Stage I adjuvant regimens (including localized intraperitoneal chemotherapy and targeted consolidation) because preventing a Stage III recurrence saves the healthcare system millions in downstream palliative care costs.

By End Users: Why Do Hospitals Remain the Dominant End-User Segment for Fallopian Tube Cancer Therapeutics Market?

By end-user, the Hospitals segment captured the highest market share in 2025, far outpacing independent oncology clinics and ambulatory surgical centers (ASCs). For stakeholders and investors mapping the supply chain, understanding hospital dominance requires looking at both clinical necessity and hospital economics.

A. Complex Administration and Toxicity Management

Fallopian tube cancer therapeutics are highly toxic. The standard Carboplatin/Paclitaxel infusions carry severe risks of hypersensitivity (anaphylaxis) and neutropenia. Furthermore, the administration of novel Antibody-Drug Conjugates (ADCs) like Mirvetuximab soravtansine (Elahere) requires rigid, multi-departmental monitoring.

For instance, Elahere carries a black-box warning for severe ocular toxicity. Its administration requires a coordinated effort between the hospital's infusion center and its ophthalmology department to conduct mandatory corneal exams prior to every single cycle. Independent clinics simply lack this integrated infrastructure.

B. Multidisciplinary Tumor Boards (MDTs)

Fallopian tube cancer is not treated by a single medical oncologist. It requires a highly coordinated tumor board comprising Gynecologic Oncologists, Pathologists (for HRD/BRCA interpretation), Surgical Oncologists, and Radiologists. This high-level, cross-functional care delivery model only exists within tertiary care hospitals and Comprehensive Cancer Centers (CCCs).

C. The Economic Moat: 340B Pricing Programs (U.S. Market Focus)

From a market revenue standpoint, hospital dominance in the U.S. fallopian tube cancer therapeutics market is heavily subsidized by the 340B Drug Pricing Program.

In 2025, qualifying hospitals purchased exorbitant oncology therapeutics (like PARP inhibitors and monoclonal antibodies) at deeply discounted rates (often 20-50% off the Average Manufacturer Price) but were reimbursed by commercial insurers at the full clinical rate. This arbitrage incentivizes hospitals to aggressively consolidate local oncology practices into Hospital Outpatient Departments (HOPDs), centralizing therapeutic purchasing power and dominating the end-user market share.

Which Geographic Regions Lead the Fallopian Tube Cancer Therapeutics Market?

North America Dominates Through Early Innovation, High Adoption, and Favorable Reimbursement Policies

North America controls the dominant share of the global fallopian tube cancer therapeutics sector. This is anchored by the US’s accelerated adoption of novel targeted therapies. Clinical data from 2024 confirms the region accounts for nearly 97% of early commercial uptake for newly approved antibody-drug conjugates. For example, AbbVie’s Elahere generated over USD 330 million in its first nine months. 

Recent epidemiological profiles show North America registers over 14,000 high-grade serous carcinoma cases annually. This high incidence drives an aggressive clinical pipeline. The fallopian tube cancer therapeutics market benefits from comprehensive genomic profiling integration. This maximizes the eligible patient pool for homologous recombination deficiency-directed PARP inhibitors. Lynparza faces a major US patent cliff by 2028. 

Consequently, leading pharmaceutical developers are intensely prioritizing next-generation combination regimens to sustain this highly lucrative regional position.

Europe Fallopian Tube Cancer Therapeutics Market Experiences Rapid Therapeutic Expansion Driven By Strong Clinical Trial Infrastructure Networks

Europe presents the highest global per capita incidence rates. These are heavily concentrated in nations with very high human development indices. Eastern and Northern Europe report uniquely elevated serous carcinoma burdens. Collectively, they account for over 17,000 annual diagnoses. This acute epidemiological pressure has catalyzed rapid regulatory advancements. The European Medicines Agency granted broader approvals for advanced therapeutics in late 2024. 

The fallopian tube cancer therapeutics market revenues are expanding significantly. Prominent drugmakers are successfully negotiating pricing frameworks across fragmented national healthcare systems. For instance, AstraZeneca highlighted robust European volume growth for Lynparza. This was bolstered by strong uptake in homologous recombination deficiency-positive patient segments. AstraZeneca also recognized a massive USD 600 million clinical milestone payment late last year. Furthermore, Europe’s robust institutional trial infrastructure continues attracting critical late-stage combinatorial pipeline investments. This solidifies its strategic, long-term market position.

Asia Pacific Presents Immense Volume Growth Accelerated By Expanding Healthcare Drug Coverage

The Asia Pacific region commands the largest absolute disease burden globally. It registers roughly 50,000 new serous carcinoma diagnoses annually across its eastern and southern territories. Historically, the region saw lower targeted therapy penetration. Now, it is exhibiting explosive volume growth driven by sweeping healthcare reforms. 

A primary catalyst behind the strong regional fallopian tube cancer therapeutics market growth is China’s National Reimbursement Drug List. China strategically included targeted fallopian tube and ovarian cancer treatments on this list. In 2024, this policy shift singlehandedly triggered immense volume surges for major pharmaceutical players. Crucially, this occurred without requiring further price reductions. 

Additionally, local biopharmaceutical companies are aggressively developing indigenous targeted therapies and diagnostics. This substantially lowers regional treatment costs. Diagnostic infrastructure is scaling across densely populated developing nations.

Top 5 Recent Developments Shaping the Fallopian Tube Cancer Therapeutics Market 

1. Daiichi Sankyo and Merck reported Phase 2 REJOICE-Ovarian01 data showing clinically meaningful response rates for raludotatug deruxtecan in platinum‑resistant ovarian, primary peritoneal, or fallopian tube cancer, with concurrent FDA Breakthrough Therapy Designation in 2025.
2. AbbVie (after acquiring ImmunoGen) received a positive CHMP opinion in 2024 for mirvetuximab soravtansine (ELAHERE) for folate receptor‑alpha–positive, platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, supporting EU approval.
3. The US FDA granted full approval to AbbVie’s ELAHERE in March 2024 for adult patients with epithelial cancers involving ovary, fallopian tube, or peritoneum who received prior therapies, reinforcing its role in this setting.
4. ​Anixa Biosciences announced in July 2024 that FDA approved an individual‑patient IND for its ovarian cancer CAR‑T program, enabling further treatment of heavily pretreated recurrent ovarian cancer patients, a population that includes fallopian tube–origin disease under the shared category.
5. GSK reported in late 2024 that the FIRST‑ENGOT‑OV44 Phase III trial of niraparib‑based regimens met its primary endpoint of progression‑free survival in first‑line ovarian cancer; trial eligibility encompassed high‑grade serous ovarian, fallopian tube, and primary peritoneal cancers collectively.

Top Companies in the Fallopian Tube Cancer Therapeutics Market

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Ipsen Group
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Roche Holding AG
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Other Prominent Players

Market Segmentation Overview

By Treatment Type

• Chemotherapy
• Targeted Therapy
• Hormonal Therapy
• Immunotherapy
• Others

By Stage

• Stage I
• Stage II
• Stage III
• Stage IV

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America